Impact of platinum/pemetrexed combination versus other platinum-based regimens on adjuvant chemotherapy in resected lung adenocarcinoma
Abstract For advanced non-squamous non-small cell lung cancer (NSCLC), although platinum/pemetrexed is known to result in a longer survival compared with other regimens, the outcome in the adjuvant setting is still unknown. In this study, the difference of the disease-free survival (DFS) between lun...
Guardado en:
Autores principales: | Xiaoyu Zhai, Qiwen Zheng, Lu Yang, Yixiang Zhu, Junling Li, Yutao Liu, Ziping Wang |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Nature Portfolio
2017
|
Materias: | |
Acceso en línea: | https://doaj.org/article/105c6a8feff241cba53acd0189624629 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Efficacy and Safety of Different Doses of Bevacizumab Combined With Pemetrexed and Platinum in First-Line Treatment of Advanced NSCLC: A Retrospective-Real World Study
por: Chun-Hua Zhou, et al.
Publicado: (2021) -
Observing the oxidation of platinum
por: Matthijs A. van Spronsen, et al.
Publicado: (2017) -
Anticancer Platinum Drugs Update
por: Giuliano Ciarimboli
Publicado: (2021) -
Cost-Effectiveness Analysis of Pembrolizumab Plus Pemetrexed and Platinum Versus Chemotherapy Alone as First-Line Treatment in Metastatic Non-Squamous Non–Small Cell Lung Cancer: A Reconstruction of Partitioned Survival Model Based on Time Dependent Pricing Mechanism of Patient Assistance Program
por: Yuanyi Cai, et al.
Publicado: (2021) -
Epidermal growth factor as a potential prognostic and predictive biomarker of response to platinum-based chemotherapy.
por: Margot Geens, et al.
Publicado: (2021)